Serial analysis of ESR1 mutations in cell-free DNA from hormone receptor-positive, HER2-negative metastatic breast cancer during palliative endocrine therapy
We observed worse outcomes in patients with persistent b<i>ESR1</i> detection during first-line endocrine therapy and then sustained positive. b<i>ESR1</i> was detected prior to clinical progression in half of patients. Our study suggests the benefit of b<i>ESR1</i> monitoring during palliative endocrine therapy.
Authors
- S. H. Kim
- J W Lee
- Tae-Kyung Yoo
- S.S. Lee
- H. Kim
- Soo Yeon Baek
- Chinkoo Jung
- Hyein Lee
- Joonseok Kim
- Meehyang Hong
- Byung Ho Son (ORCID: https://orcid.org/0000-0001-9137-1162)
- Seulgi Joo
- JungPil Jang
- Gyungyub Gong
- Jae Jeong
- Beom Seok Ko (ORCID: https://orcid.org/0000-0001-7831-7874)
- Hyehyun Jeong
- Il Yong Chung
- Kyung Hae Jung
- Sae Byul Lee
- Hee Jin Lee
- Jin-Hee Ahn
Institutions
- Asan Medical Center (KR)
- University of Ulsan (KR)
- Genoscope (FR)
- Ajou University (KR)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-01-06
- DOI
- https://doi.org/10.3389/fonc.2025.1709317
- Primary Topic
- Estrogen and related hormone effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Asan Institute for Life Sciences, Asan Medical Center